<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg"/></p>
<p>英矽智能的商业模式包括与 13 家跨国制药公司进行软件解决方案授权。图片来源：metamorworks / Shutterstock.com。</p>
<p>英矽智能与齐鲁制药及其子公司上海齐鲁制药研究中心在心脏代谢疾病的药物开发方面达成战略合作。</p>
<p>该合作将利用英矽智能的 Pharma.AI 平台开发小分子抑制剂，协议价值近 1.2 亿美元。</p>
<p>该协议包括开发和商业里程碑付款，以及基于净销售额的单数字版税。</p>
<p>根据协议，英矽智能将设计和优化用于治疗代谢疾病的小分子。</p>
<p>齐鲁制药将负责后续的开发和商业化活动。</p>
<p>英矽智能的商业模式包括与 13 家跨国制药公司进行软件解决方案授权，以及与赛诺菲和复星医药的研究合作，涉及预付款项。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>该公司还将与 Menarini 集团和 Exelixis 签署总额超过 20 亿美元的管线外授权协议。</p>
<p>齐鲁制药于 2021 年首次采用 PandaOmics，这促成了此次新的 1.2 亿美元合作。</p>
<p>英矽智能创始人、首席执行官兼首席商务官亚历克斯·扎沃伦科表示：“我们很高兴看到英矽智能与齐鲁制药进一步深化由生成性人工智能驱动的战略合作。</p>
<p>“我相信，针对心脏代谢疾病的策略有潜力产生首批实现大规模健康寿命延长的药物，我期待人工智能技术加速该领域的创新并最大化潜力。”</p>
<p>在 2025 年 3 月，英矽智能完成了一轮 E 轮融资，筹集了 1.1 亿美元，以推进其药物管线和人工智能平台的发展。</p>

英矽智能

<p>英矽智能与齐鲁制药签署了一项价值 1.2 亿美元的协议，旨在利用英矽智能的 Pharma.AI 平台开发心脏代谢疗法。该协议包括里程碑付款和基于净销售的特许权使用费。英矽智能将设计用于代谢疾病的小分子，而齐鲁制药将负责开发和商业化。这一合作建立在齐鲁制药 2021 年采用英矽智能的 PandaOmics 基础之上。英矽智能的首席执行官对人工智能在加速心脏代谢疾病药物创新方面的潜力表示乐观</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-28-01-2026-shutterstock_2306050281-430x241.jpg"/></p>
<p>Insilico’s business model includes software solution licensing with 13 multinational pharma companies. Credit: metamorworks / Shutterstock.com.</p>
<div class="lb-trans"><p>英矽智能的商业模式包括与 13 家跨国制药公司进行软件解决方案授权。图片来源：metamorworks / Shutterstock.com。</p>
</div><p>Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug development for cardiometabolic diseases.</p>
<div class="lb-trans"><p>英矽智能与齐鲁制药及其子公司上海齐鲁制药研究中心在心脏代谢疾病的药物开发方面达成战略合作。</p>
</div><p>The partnership will leverage Insilico’s Pharma.AI platform for the development of small molecule inhibitors, with the agreement valued at nearly $120m.</p>
<div class="lb-trans"><p>该合作将利用英矽智能的 Pharma.AI 平台开发小分子抑制剂，协议价值近 1.2 亿美元。</p>
</div><p>This agreement includes development and commercial milestone payments plus single-digit royalties based on net sales.</p>
<div class="lb-trans"><p>该协议包括开发和商业里程碑付款，以及基于净销售额的单数字版税。</p>
</div><p>Under the agreement, Insilico will design and optimise small molecules for treating metabolic disorders.</p>
<div class="lb-trans"><p>根据协议，英矽智能将设计和优化用于治疗代谢疾病的小分子。</p>
</div><p>Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.</p>
<div class="lb-trans"><p>齐鲁制药将负责后续的开发和商业化活动。</p>
</div><p>Insilico’s business model includes software solution licensing with 13 multinational pharma companies, research collaborations involving upfront payments with Sanofi and Fosun Pharma.</p>
<div class="lb-trans"><p>英矽智能的商业模式包括与 13 家跨国制药公司进行软件解决方案授权，以及与赛诺菲和复星医药的研究合作，涉及预付款项。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>The company will also sign pipeline out-licensing deals with Menarini Group and Exelixis totalling more than $2bn.</p>
<div class="lb-trans"><p>该公司还将与 Menarini 集团和 Exelixis 签署总额超过 20 亿美元的管线外授权协议。</p>
</div><p>Qilu Pharmaceutical initially adopted PandaOmics in 2021, which led to this new $120m collaboration.</p>
<div class="lb-trans"><p>齐鲁制药于 2021 年首次采用 PandaOmics，这促成了此次新的 1.2 亿美元合作。</p>
</div><p>Insilico founder, CEO and chief business officer Alex Zhavoronkov said: “We are pleased to see Insilico Medicine and Qilu Pharmaceutical further deepen their strategic collaboration driven by generative AI.</p>
<div class="lb-trans"><p>英矽智能创始人、首席执行官兼首席商务官亚历克斯·扎沃伦科表示：“我们很高兴看到英矽智能与齐鲁制药进一步深化由生成性人工智能驱动的战略合作。</p>
</div><p>“I believe that strategies targeting cardiometabolic diseases have the potential to generate the first drugs to achieve large-scale healthspan extension, and I look forward to AI technology accelerating innovation in the field and maximising potential.”</p>
<div class="lb-trans"><p>“我相信，针对心脏代谢疾病的策略有潜力产生首批实现大规模健康寿命延长的药物，我期待人工智能技术加速该领域的创新并最大化潜力。”</p>
</div><p>In March 2025, Insilico Medicine completed a Series E financing round, raising $110m to progress the development of its pipeline of drugs and AI platform.</p>
<div class="lb-trans"><p>在 2025 年 3 月，英矽智能完成了一轮 E 轮融资，筹集了 1.1 亿美元，以推进其药物管线和人工智能平台的发展。</p>
</div>

英矽智能与齐鲁制药签署心脏代谢治疗协议